ReviewEnvironmental monitoring and assessment2025
Pharmaceutical waste management through microbial bioremediation.
Review in Environmental monitoring and assessment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Synergies of Quorum Sensing and Biofilm Dynamics in the Bioremediation of Emerging Medical Organic Pollutants.TheScientificWorldJournal · 2026Review
- Advanced microbial engineering approaches for biodegradation of pharmaceutical pollutants.Biodegradation · 2025Review
- Bibliometric Analysis and Review of Global Academic Research on Drug Take-Back Programs.Healthcare (Basel, Switzerland) · 2025Review
- Sustainable strategies for hospital wastewater treatment: bioremediation, phytoremediation, and hybrid approaches for emerging pollutants.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceuticals play a significant role in enhancing the quality of life. However, pharmaceutical products (PPs) manufacturing presents challenges, particularly in terms of waste generated, posing a risk to the ecosystem. Existing physical and chemical remediation methods are expensive and are not directly applicable for pharmaceutical remediation. Bioremediation using various microbial consortia has the potential to become a cost-effective solution when applied optimally. This review highlights the various pharmaceutical products, their occurrence in the environment, and their associated health risks. Further, various microorganisms employed in the bioremediation process and the techniques utilized to degrade diverse categories of pharmaceutical pollutants are discussed. Finally, the review highlights the limitations of using bioremediation for treating pharmaceutical waste and discusses alternative sustainable green pharmacy approaches to reduce the impact of pharmaceutical contaminants on the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.